All In Biotech

Drug Trial Radar · NCT02944214

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Middle-to-late Stages of Chronic Kidney Disease Patients: a Multi-center Randomized Controlled Study

Last checked: Nov 20, 2026Latest source record: Oct 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Oct 2016

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Shanghai 10th People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.

Conditions

  • Chronic Kidney Disease
  • Hyperuricemia
  • Abnormal Renal Function

Interventions

  • FebuxostatDrug

    It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body

  • BenzbromaroneDrug

    It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. serum creatinine, estimated glomerular filtration rate (eGFR)Time frame: up to 12th months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.